Cyclic Nucleotide Phosphodiesterases, Type 5
"Cyclic Nucleotide Phosphodiesterases, Type 5" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A cyclic nucleotide phosphodiesterase subfamily that is highly specific for CYCLIC GMP. It is found predominantly in vascular tissue and plays an important role in regulating VASCULAR SMOOTH MUSCLE contraction.
MeSH Number(s)
D08.811.277.352.640.150.500
D08.811.277.352.640.155.500
D12.644.360.008.500
D12.644.360.009.500
D12.776.476.008.500
D12.776.476.009.500
Concept/Terms
Cyclic Nucleotide Phosphodiesterases, Type 5- Cyclic Nucleotide Phosphodiesterases, Type 5
- Phosphodiesterase-5
- Phosphodiesterase 5
- Phosphodiesterase V
- cGMP-Binding, cGMP-Specific 3',5'-cyclic Nucleotide Phosphodiesterase
- PDE5 Phosphodiesterases
- Phosphodiesterases, PDE5
Below are MeSH descriptors whose meaning is more general than "Cyclic Nucleotide Phosphodiesterases, Type 5".
- Chemicals and Drugs [D]
- Enzymes and Coenzymes [D08]
- Enzymes [D08.811]
- Hydrolases [D08.811.277]
- Esterases [D08.811.277.352]
- Phosphoric Diester Hydrolases [D08.811.277.352.640]
- 3',5'-Cyclic-AMP Phosphodiesterases [D08.811.277.352.640.150]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.150.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D08.811.277.352.640.155]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D08.811.277.352.640.155.500]
- Amino Acids, Peptides, and Proteins [D12]
- Peptides [D12.644]
- Intracellular Signaling Peptides and Proteins [D12.644.360]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.644.360.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.644.360.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.644.360.009.500]
- Proteins [D12.776]
- Intracellular Signaling Peptides and Proteins [D12.776.476]
- 3',5'-Cyclic-AMP Phosphodiesterases [D12.776.476.008]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.008.500]
- 3',5'-Cyclic-GMP Phosphodiesterases [D12.776.476.009]
- Cyclic Nucleotide Phosphodiesterases, Type 5 [D12.776.476.009.500]
Below are MeSH descriptors whose meaning is more specific than "Cyclic Nucleotide Phosphodiesterases, Type 5".
This graph shows the total number of publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Harvard Catalyst Profiles by year, and whether "Cyclic Nucleotide Phosphodiesterases, Type 5" was a major or minor topic of these publication.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2000 | 0 | 1 | 1 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 1 | 1 |
| 2006 | 1 | 1 | 2 |
| 2007 | 0 | 2 | 2 |
| 2009 | 0 | 1 | 1 |
| 2010 | 1 | 0 | 1 |
| 2011 | 0 | 1 | 1 |
| 2012 | 1 | 0 | 1 |
| 2013 | 2 | 0 | 2 |
| 2014 | 1 | 0 | 1 |
| 2015 | 0 | 2 | 2 |
| 2018 | 1 | 0 | 1 |
| 2019 | 1 | 2 | 3 |
| 2021 | 0 | 1 | 1 |
| 2022 | 0 | 2 | 2 |
Below are the most recent publications written about "Cyclic Nucleotide Phosphodiesterases, Type 5" by people in Profiles.
-
The NO/cGMP/PKG pathway in platelets: The therapeutic potential of PDE5 inhibitors in platelet disorders. J Thromb Haemost. 2022 11; 20(11):2465-2474.
-
Outcomes With Phosphodiesterase-5 Inhibitor Use After Left Ventricular Assist Device: An STS-INTERMACS Analysis. Circ Heart Fail. 2022 04; 15(4):e008613.
-
The effect of phosphodiesterase-5 inhibitors on uteroplacental and fetal cerebral perfusion in pregnancies with fetal growth restriction: A systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol. 2021 Dec; 267:129-136.
-
Are Phosphodiesterase-5 Inhibitors a New Frontier for Prevention of Colorectal Cancer? Gastroenterology. 2019 09; 157(3):602-604.
-
Preimplant Phosphodiesterase-5 Inhibitor Use Is Associated With Higher Rates of Severe Early Right Heart Failure After Left Ventricular Assist Device Implantation. Circ Heart Fail. 2019 06; 12(6):e005537.
-
Low guanylyl cyclase activity in Weddell seals: implications for peripheral vasoconstriction and perfusion of the brain during diving. Am J Physiol Regul Integr Comp Physiol. 2019 06 01; 316(6):R704-R715.
-
Novel Mechanism for Cyclic Dinucleotide Degradation Revealed by Structural Studies of Vibrio Phosphodiesterase V-cGAP3. J Mol Biol. 2018 12 07; 430(24):5080-5093.
-
Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. Am J Physiol Endocrinol Metab. 2018 10 01; 315(4):E446-E453.
-
Pulmonary Hypertension: Good Intentions, But a Questionable Approach. Ann Am Thorac Soc. 2018 06; 15(6):664-666.
-
Phosphodiesterase 5 Inhibition Limits Doxorubicin-induced Heart Failure by Attenuating Protein Kinase G Ia Oxidation. J Biol Chem. 2016 08 12; 291(33):17427-36.